Pralidoxime Iodide

Note: This product is not licenced in Australia at the time of publication. The information in this monograph applies to the specified brand, formulation and strength only.

Trade name

PAM (Phebra)

Strength

25 mg/mL (volume: 20 mL)

IV administration

Give undiluted or dilute to 10 mg/mL and give over 15 minutes, followed by a continuous infusion at a rate of 10 mg/kg/hour (maximum 250 mg/hour).

Other routes of administration

IV is the preferred route due to rapid effect.

IM: Suitable.

SC: No information.

Compatible IV fluids

Sodium chloride 0.9%

Additional information

Rapid administration may cause tachycardia, laryngospasm and muscle rigidity.

Use when facilities for cardiac monitoring and cardio-respiratory resuscitation exist.

Solution should be clear and colourless or slightly straw-coloured.

Protect from light during storage.

Contact the Poisons Information Centre for more detailed information: 13 11 26.